Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen EPOGEN (epoetin alfa by Quarter
EPOGEN (epoetin alfa — Dialysis Anemia, legacy standalone disclosure) — Rest of World (ROW) product sales ($M) ($M)
Amgen EPOGEN (epoetin alfa: $0M in Q4 2019. That is the highest of the 12 quarters on record here. No newer figure appears in the documents we track.
Where the Q4 2019 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K (filed 2020-02-12) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | EPOGEN (epoetin alfa — Dialysis Anemia, legacy standalone disclosure) — Rest of World (ROW) product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2020-02-12) ↗ |
| Q3 2019 | Sep 30, 2019 | 0 | – | Form 10-Q (filed 2019-10-30) ↗ |
| Q2 2019 | Jun 30, 2019 | 0 | – | Form 10-Q (filed 2019-07-31) ↗ |
| Q1 2019 | Mar 31, 2019 | 0 | – | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 0 | – | Form 10-K (filed 2019-02-13) ↗ |
| Q3 2018 | Sep 30, 2018 | 0 | – | Form 10-Q (filed 2019-10-30) ↗ |
| Q2 2018 | Jun 30, 2018 | 0 | – | Form 10-Q (filed 2019-07-31) ↗ |
| Q1 2018 | Mar 31, 2018 | 0 | – | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 0 | – | Form 10-K (filed 2019-02-13) ↗ |
| Q3 2017 | Sep 30, 2017 | 0 | – | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2017 | Jun 30, 2017 | 0 | – | Form 10-Q (filed 2018-07-27) ↗ |
| Q1 2017 | Mar 31, 2017 | 0 | – | Form 10-Q (filed 2018-04-25) ↗ |
Cite this data
StockData. (2026). Amgen EPOGEN (epoetin alfa ($M), quarterly Q1 2017–Q4 2019 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-epogen-row
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.